Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Citi
Boehringer Ingelheim
McKinsey
US Department of Justice
Harvard Business School

Generated: July 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,012,437

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,012,437 protect, and when does it expire?

Patent 9,012,437 protects OZURDEX and is included in one NDA.

This patent has eighteen patent family members in twelve countries.

Summary for Patent: 9,012,437
Title:Implants and methods for treating inflammation-mediated conditions of the eye
Abstract: Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.
Inventor(s): Wong; Vernon G. (Menlo Park, CA), Hu; Mae W. L. (Los Altos, CA)
Assignee: Allergan, Inc. (Irvine, CA)
Application Number:13/886,465
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,012,437
Patent Claim Types:
see list of patent claims
Use; Device;

Drugs Protected by US Patent 9,012,437

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan OZURDEX dexamethasone IMPLANT;INTRAVITREAL 022315-001 Jun 17, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial TREATMENT OF MACULAR EDEMA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 9,012,437

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 029567 ➤ Try a Free Trial
Austria 339185 ➤ Try a Free Trial
Australia 2001273166 ➤ Try a Free Trial
Australia 2005246995 ➤ Try a Free Trial
Australia 7316601 ➤ Try a Free Trial
Brazil 0112361 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Healthtrust
AstraZeneca
Baxter
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.